Matrix Metalloproteinase 9 Gene Promoter (rs 3918242) Mutation Reduces the Risk of Diabetic Microvascular Complications

Zhang, Zhongwen; Wu, Xiaoyun; Cai, Tian; Gao, Weiyi; Zhou, Xiaojun; Zhao, Jingbo; Yao, Jinming; Shang, Hongxia; Dong, Jianjun; Li, Lin

doi:10.3390/ijerph120708023

Cited by 18 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, it is observed in the present study that subjects with fasting blood glucose equals or exceed 5.5 mmol/L have a significant higher level of serum MMP-9 level compared to subjects without hyperglycemia, suggesting that the upregulation of MMP-9 occurs before the fasting blood glucose level has reached to clinical diabetic level. MMP-9 is associated with several pathological changes of diabetes mellitus including diabetic retinopathy [ 52 ], diabetic nephropathy [ 10 ] and diabetic microvascular complications due to its contribution in microvascular remodeling [ 53 ]. Upregulation of MMP-9 has been observed during the development of diabetic microvascular complications [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

“…MMP-9 is associated with several pathological changes of diabetes mellitus including diabetic retinopathy [ 52 ], diabetic nephropathy [ 10 ] and diabetic microvascular complications due to its contribution in microvascular remodeling [ 53 ]. Upregulation of MMP-9 has been observed during the development of diabetic microvascular complications [ 53 ]. The high abundance of MMP-9 is also associated with the recruitment of leukocytes to lesions and fibrosis of the microvascular wall [ 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

“…Genetic variances on MMP-9 gene are demonstrated to be associated with the risk of developing diabetic microvascular complications. A study of meta-analysis has revealed that mutation of the promoter of MMP-9 gene decreases the risk of diabetic nephropathy [ 53 ]. The involvement of MMP-9 in the early hypertensive remodeling has been demonstrated [ 26 ] while MMP-9 has been suggested as a biomarker for acute coronary syndrome [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults

Tam

Yau

et al. 2015

Diabetol Metab Syndr

View full text Add to dashboard Cite

BackgroundMetabolic syndrome (MetS) contains a cluster of cardiovascular risk factors. People with MetS are more susceptible to cardiovascular disease, diabetes mellitus, and cancer. Endothelin-1 (ET-1) and matrix metallopeptidase-9 (MMP-9) have been implicated in the development of cardiovascular diseases, diabetes mellitus and cancers. This cross-sectional study aimed to examine the association of ET-1 and MMP-9 with MetS in middle-aged and older Hong Kong Chinese adults.Methods149 adults aged 50 to 92 (n = 75 for non-MetS group and n = 74 for MetS group) were examined. All subjects were screened for MetS according to the diagnostic guideline of the United States National Cholesterol Education Program (NCEP) Expert Panel Adult Treatment Panel (ATP) III criteria. Serum levels of ET-1 and MMP-9 were measured. Independent t test was used to detect differences between non-MetS and MetS groups and between subjects with or without certain metabolic abnormality. The association of the serum concentration of MMP-9 and ET-1 with MetS parameters were examined by Pearson’s correlation analysis.ResultsSerum level of ET-1 is higher in MetS-positive subjects and in subjects with high blood pressure, elevated fasting blood glucose, and central obesity. The serum concentration of MMP-9 is higher in subjects positively diagnosed with MetS and subjects with high blood pressure, elevated fasting blood glucose, low blood high-density lipoprotein-cholesterol (HDL-C), high blood triglycerides, and central obesity. Correlation analyses revealed that serum concentration of ET-1 is positively correlated to systolic blood pressure, waist circumference, fasting blood glucose, and age whereas it is negatively correlated to HDL-C. MMP-9 is positively correlated to systolic blood pressure, waist circumference, fasting blood glucose, and age whereas it is negatively correlated to HDL-C.ConclusionSerum ET-1 is higher in subjects with hypertension, hyperglycemia, central obesity or MetS. Serum MMP-9 is higher in subjects diagnosed with MetS or having either one of the MetS parameters. Both circulating levels of ET-1 and MMP-9 are correlated to systolic blood pressure, waist circumference, fasting blood glucose, HDL-C, and age. Further research is needed to fully dissect the role of ET-1 and MMP-9 in the development of cancers, diabetes and cardiovascular disease in relation to MetS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults

Tam

Yau

et al. 2015

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…[ 25 – 27 ] The most common variants are microsatellites (CA)n [ 28 ] and rs3918242 (-1562C/T) [ 26 , 27 ] promoter polymorphisms. A recent meta-analysis provided potential evidence of the association between MMP-9 gene promoter polymorphism and the risk of diabetic microvascular complications, [ 26 ] but there is no system review specifically evaluating MMP-9 SNPs in DN to date. Fortunately, meta-analysis has been applied successfully in multiple researches to annihilate confounding results and evaluate the relationship based on a larger sample size.…”

Section: Introductionmentioning

confidence: 99%

Association of MMP-9 polymorphisms with diabetic nephropathy risk

Xie¹,

Wang²,

Chang³

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Diabetic nephropathy (DN) is a multifactorial disease with gene–environment interaction resulting in progressive renal function damage. Multiple studies have assessed the association between matrix metalloproteinase-9 (MMP-9) gene promoter polymorphism and DN susceptibility. However, the results are inconclusive. In the present study, we will conduct a meta-analysis to further examine this relationship more precisely. Methods: Electronic databases (Pubmed, Web of Science, Embase, Google Scholar, Wanfang, China Biological Medicine and China National Knowledge Infrastructure) will be used to search clinical case–control studies about MMP-9 polymorphism and DN published until 18 August 2020. The language will be restricted to Chinese and English. Two reviewers will take charge of completing the selection of study, the extraction of data as well as the assessment of study quality independently. The Newcastle-Ottawa Scale will be used to evaluate the study quality. We will evaluate the association under 5 genetic models. Fixed-effects or random-effects models will be used to calculate the effect sizes of odds ratio and 95% confidence intervals. Afterwards, subgroup analysis will be conducted in terms of the ethnicity and genotyping method. Additionally, sensitivity analysis will be performed via sequentially omitting each of the included studies one at a time. The funnel plots, Egger regression test, and Begg rank correlation test will be used to test the potential publication bias. All the statistical analyses will be performed using Review Manager 5.3 and Stata 12.0. Results: This protocol reported according to the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement. This study will provide a better understanding of the association between MMP-9 polymorphisms and DN risk. Conclusion: Publishing this protocol will minimize the potential bias related to data mining, thus contributing to generation of reliable evidence. OSF registration number: DOI 10.17605/OSF.IO/H5FS4

show abstract

“…In recent years, with the improvement of people’s living standard, the incidence and prevalence of diabetes are increasing year by year. Diabetes has become a serious social problem threatening people’s health and caused widespread concern in the world [1–3].…”

Section: Introductionmentioning

confidence: 99%

ATP-binding cassette sub-family a member1 gene mutation improves lipid metabolic abnormalities in diabetes mellitus

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Patients with diabetes mellitus were often accompanied with hyperlipidemia. ATP-binding cassette sub-family A member1 (ABCA1) promotes the efflux of lipids and thereby mediates the metabolism of cholesterol. The aim of our study was to determine the associations of ABCA1 gene polymorphisms with the risks of diabetes mellitus and dyslipidemia in diabetic patients. Methods We retrieved literature about the relationship between ABCA1 gene polymorphisms (C69T and R230C) and the risk of diabetes through PubMed, Web of Science, EMBASE, Wanfang Database, China National Knowledge Infrastructure (CNKI) and Cochrane database. Weighted mean difference (WMD) and odds ratio (OR) were used to compare continuous and dichotomous variables, respectively, accompanied by their 95% confidence interval (CI). Results A total of 1746 diabetic patients and 1292 non-diabetic controls were enrolled. All subjects were Caucasians. ABCA1 R230C T allele was significantly associated with reduced the risk of diabetes (OR = 0.75, 95% CI = 0.57–0.98, P = 0.04). There was no association of ABCA1 C69T gene polymorphisms with the risk of diabetes. However, subgroup analyses showed that the ABCA1 C69T gene mutation significantly reduced the risk of hypertriglyceridemia in diabetic patients as compared with that in non-diabetic subjects (dominant model: WMD =0.66, 95% CI = 0.52–0.8, P < 0.0001; recessive model: WMD = 0.47, 95%CI = 0.11–0.83, P = 0.01). Conclusions ABCA1 R230C T allele gene mutation is a protective in decreasing the risk of diabetes in Caucasians and ABCA1 C69T gene mutation markedly influences the level of lipid metabolism in diabetic patients. Electronic supplementary material The online version of this article (10.1186/s12944-019-0998-3) contains supplementary material, which is available to authorized users.

show abstract

Matrix Metalloproteinase 9 Gene Promoter (rs 3918242) Mutation Reduces the Risk of Diabetic Microvascular Complications

Cited by 18 publications

References 33 publications

Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults

Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults

Association of MMP-9 polymorphisms with diabetic nephropathy risk

ATP-binding cassette sub-family a member1 gene mutation improves lipid metabolic abnormalities in diabetes mellitus

Contact Info

Product

Resources

About